The results of Phase 1a will be included in a poster presentation at the San Antonio Breast Cancer Symposium being held on December 4-8, 2018.
This trial is being conducted at Tracer Center of Expertise, University Medical Center Groningen in Groningen, The Netherlands with Professor Go van Dam as the Principal Investigator.
The Phase 1b portion of the study is currently enrolling patients and is an expansion phase at the highest dose tested in Phase 1a.
In addition to testing for breast cancer and head and neck squamous cell carcinoma (HNSCC) which were studied in Phase 1a, Phase 1b includes patients with colorectal and esophageal cancers.
Surgery remains the standard treatment for most solid tumors, with postoperative margin status and tumors left behind being the leading prognostic factor to predict tumor metastasis and potential recurrence.
Despite tremendous advances in imaging modalities, current techniques do not provide real-time feedback and surgeons must rely upon pre-operative imaging data with visual information during surgery.
ONM-100 targets the acidic pH environment within tumors, potentially providing surgeons with a method to assess lymph nodes and tumor margins in real-time. ONM-100 features a digital on-off response to pH changes switching on in the tumor's acidic environment and remaining off in blood circulation and normal cells.
OncoNano Medicine is developing a new class of pH-activated compounds that digitalise and exploit the variability of pH in disease.
pH variability is an identifier of diseased tissue and provides a foundation for the development of a range of highly targeted therapeutics and imaging agents.
OncoNano said it is the first company to advance product candidates using pH as a biomarker for cancer immunotherapy, therapeutic use and intra-operative imaging based on its pH-sensitive micelle technology.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval